Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Crossject Appoints Dan Chiche, Md As Chief Medical Officer North America

PRIVATEJun 12, 2024•about 2 years ago

Position

Chief Medical Officer

Company

CROSSJECT

Dan Chiche

DijonBiotechnologyPharmaceutical

Description

Crossject announces the appointment of Dan Chiche, MD as Chief Medical Officer North America, reinforcing the company's leadership team and expanding its presence in North America. This appointment aims to support processes targeting ZEPIZURE® regulatory milestones in the U.S. in 2025.

Company Information

Company

CROSSJECT

Location

Dijon, Bourgogne – Franche-Comté, France

About

Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for CROSSJECT's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months